Is RDY a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for RDY (RDY) rests on Biosimilars ramp: Dr. Revenue (FY26) is ~$4.0B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. Whether RDY is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India. The FY2026 investment picture is defined by a transition. Dr. Reddy's limited-competition window on generic Revlimid (lenalidomide) ended on January 31, 2026, removing an outsized, high-margin US profit stream (previously estimated near $250 million of quarterly revenue), which crushed Q4 FY26 margins and profit. Management is pivoting toward biosimilars (denosumab, rituximab), generic GLP-1 weight-loss and diabetes therapy (semaglutide, launched in Canada and India), and the acquired ex-US Nicotinell nicotine-replacement consumer-health business bought from Haleon. The core company remains solidly profitable and cash-generative, so the debate is about the pace and quality of growth that replaces the Revlimid windfall.
What's the case for buying RDY?
1. Biosimilars ramp
Dr. Reddy's is building a biosimilar franchise to offset the small-molecule generic squeeze, with denosumab launched in the EU, rituximab approved in Canada in February 2026, and US biosimilar entries targeted for 2026-2027. Biosimilars carry higher barriers to entry and longer competitive runways than plain generics, which could support more durable margins if launches land on schedule.
2. GLP-1 / semaglutide opportunity
The company was first to market generic semaglutide injection in Canada (launched May 2026) and launched it in India under the brand Obeda on day one of loss of exclusivity, plus received authorization for semaglutide tablets in India. GLP-1 weight-loss and diabetes demand is very large, and early-mover generic positioning in markets where exclusivity has lapsed is a potential multi-year growth lever.
3. Consumer health and Nicotinell
Dr. Reddy's acquired Haleon's ex-US nicotine-replacement-therapy business (Nicotinell and related brands) for roughly 500 million pounds (about $633 million), adding a branded consumer-health revenue stream generating around 217 million pounds in annual sales. This diversifies the mix away from volatile US generics toward steadier branded OTC cash flows.
4. Diversified geographic base
Beyond the US, the company earns meaningful revenue in India, Russia and CIS, Europe, and other emerging markets, which cushions US pricing pressure. A broad API and formulations manufacturing footprint gives it vertical integration and cost control across its portfolio.
What are the risks to RDY?
The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.
How is RDY valued? (as of July 2026)
Snapshot for RDY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY26): ~$4.0B
- Market cap: ~$12.8B
- P/E (normalized): ~27x
- FY26 EBITDA margin: ~22.8%
- Forward dividend yield: ~0.6%
- FY26 revenue growth: ~3.2%
FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.
How do you decide if RDY is a buy?
Rather than asking whether RDY is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold RDY indirectly through an index or sector ETF before adding more.
For the full picture, see the RDY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RDY against your real portfolio and see your actual exposure before deciding.
The bottom line on RDY
The bottom line: RDY's story right now is Biosimilars ramp, with revenue (fy26) at ~$4.0B. If you believe that narrative continues, the call is about sizing RDY sensibly and checking overlap with what you own; if you doubt it (the risk: the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around RDY with Walnut
Use RDY as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is RDY a good stock to buy right now?
+
The case for RDY right now is Biosimilars ramp, with revenue (fy26) at ~$4.0B. If you believe that thesis holds, RDY is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does RDY do?
+
Dr.
What are the main risks of RDY?
+
The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.
What is RDY?
+
RDY is the NYSE-listed American Depositary Receipt (ADR) of Dr. Reddy's Laboratories, a large Indian pharmaceutical company that makes generics, branded generics, biosimilars, APIs, and over-the-counter products. It also lists on Indian exchanges.
Is RDY a US company?
+
No. Dr. Reddy's is headquartered in Hyderabad, India, and RDY is an ADR that lets US investors hold the shares in dollars on the NYSE. That means currency and India-specific regulatory factors apply.
What is the Revlimid cliff and why does it matter?
+
Dr. Reddy's limited-competition period for generic Revlimid (lenalidomide) ended January 31, 2026, opening the market to unlimited competitors. That removed a large, high-margin US profit stream (previously near $250 million of quarterly revenue), which sharply pressured FY26 Q4 profit and margins.
How is Dr. Reddy's trying to replace that revenue?
+
It is scaling biosimilars (denosumab, rituximab), generic GLP-1 therapies like semaglutide (launched in Canada and India), and the acquired ex-US Nicotinell nicotine-replacement consumer-health business. The open question is how quickly these ramp relative to the Revlimid decline.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell RDY; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.